Atropine + Physostigmine + Placebo Sodium
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Insulin Resistance
Conditions
Insulin Resistance
Trial Timeline
May 1, 2007 → Nov 1, 2008
NCT ID
NCT00689208About Atropine + Physostigmine + Placebo Sodium
Atropine + Physostigmine + Placebo Sodium is a phase 1 stage product being developed by AstraZeneca for Insulin Resistance. The current trial status is completed. This product is registered under clinical trial identifier NCT00689208. Target conditions include Insulin Resistance.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00689208 | Phase 1 | Completed |
Competing Products
20 competing products in Insulin Resistance